Interim Safety Results of Amlitelimab (anti-OX40 ligand antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2/3 Ongoing Open-Label Study. J of Skin. 2025;9(6):s602. doi:10.25251/mq5bgn88